



May 7, 2025

The Honorable Thom Tillis
Chairman
Subcommittee on Intellectual Property
Committee on the Judiciary
United States Senate
Washington, D.C. 20510
Peter_Pappas@judiciary-rep.senate.gov

The Honorable Chris Coons
Ranking Minority Member
Subcommittee on Intellectual Property
Committee on the Judiciary
United State Senate
Washington, D.C. 20510
James_Barton@judiciary-dem.senate.gov

By E-mail

Re: Patent Eligibility Restoration Act of 2025 ("PERA 2025")

Dear Chairman Tillis and Ranking Minority Member Coons:

REGENXBIO commends you both for your efforts in drafting and re-introducing the Patent Eligibility Restoration Act, 2025 ("PERA 2025"). This bipartisan, bicameral legislation will confirm patent eligibility of many inventions in the biotech sector using a balanced approach to address legitimate concerns of skeptics. We have sent letters supporting the legislation to each member of the Subcommittee on Intellectual Property and hope it will be scheduled for mark up soon. We are prepared to work with you and other stakeholders as the language is refined and, as we hope, adopted into law.

REGENXBIO is a clinical stage biotech company headquartered in Rockville, Maryland that is developing gene therapies for serious life-threatening conditions. Our technology platform, originated at the University of Pennsylvania, is the foundation for gene therapies that we have translated to the clinic for the benefit of patients. Using a single treatment, our gene therapies

Honorable Thom Tillis
Honorable Christopher A. Coons
May 7, 2025
Page 2 of 2

have the potential to correct disease allowing the body's natural mechanisms to work the way they were intended.

We are developing gene therapies for retinal, metabolic, and neurodegenerative diseases. In addition to our own clinical programs, REGENXBIO has partnered with others to enable the development of gene therapies based on our technology platform across a broad range of therapeutic areas and disease indications, including in an FDA-approved gene therapy for spinal muscular atrophy, a devastating, fatal genetic condition.

If Congress acts to restore balance, predictability, and fairness into Section 101 of the Patent Code, many biotechnology companies, academic medical research centers, life science inventors, and – most importantly, patient advocacy organizations and families facing the enormous challenges presented by untreatable diseases stand to benefit. PERA 2025 promises not only to facilitate the creation of next generation medical treatments but would also support America's continued world leadership in biomedical innovation and the employment opportunities for highly skilled U.S. workers that follow.

Because of the potential positive impact that the Section 101 reforms proposed in PERA 2025 could have on REGENXBIO and other biotech firms developing new treatments that may change the practice of medicine and the course of disease for literally millions of patients, we urge that the Judiciary Committee take expeditious action to mark up and favorably report the bill to the Senate Floor.

In closing, we note that both of you have been well served by your respective staffs working with a diverse group of intellectual property lawyers on this complex matter of patent law. Once again thank you both for working across the aisle and developing this legislation, and we assure you that we and many others stand ready to work with you during the mark up process and beyond.

Yours truly,

DocuSigned by:
Patrick Christmas
E8080778EE25459...
Patrick J. Christmas II, J.D.
Chief Legal Officer